Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy

References

• Perminow G, Brackmann S, Lyckander LG, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005–07, showing increased incidence in Crohn's disease. Scand J Gastroenterol. 2009;44:446–456.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423–439.
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–1122.
   PubMed Web of Science ®Google Scholar
• Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135:1106–1113.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Standaert-Vitse A, Branche J, et al. IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007;13:1561–1566.
   PubMed Web of Science ®Google Scholar
• Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123:689–699.
   PubMed Web of Science ®Google Scholar
• Dubinsky M. Can serologic markers help determine prognosis and guide therapy? Dig Dis. 2010;28:424–428.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6:1105–1111.
   PubMed Web of Science ®Google Scholar
• Olbjørn C, Nakstad B, Smastuen MC, et al. Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients. Scand J Gastroenterol. 2014;49:1425–1431.
   PubMed Web of Science ®Google Scholar
• Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.
   PubMed Web of Science ®Google Scholar
• Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–1321.
   PubMed Web of Science ®Google Scholar
• Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41:416–421.
   PubMed Web of Science ®Google Scholar
• Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423–432.
   PubMed Web of Science ®Google Scholar
• IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis–the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1–7.
   PubMed Web of Science ®Google Scholar
• Ryan JD, Silverberg MS, Xu W, et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther. 2013;38:274–283.
   PubMed Web of Science ®Google Scholar
• Kovacs M, Muller KE, Papp M, et al. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol. 2014;20:4873–4882.
   PubMed Web of Science ®Google Scholar
• Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol. 2006;101:645–652.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Cvancarova M, et al. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:406–414.
   PubMed Web of Science ®Google Scholar
• Kaur M, Panikkath D, Yan X, et al. Perianal Crohn's disease is associated with distal colonic disease, stricturing disease behavior, IBD-associated serologies and genetic variation in the JAK-STAT pathway. Inflamm Bowel Dis. 2016;22:862–869.
   PubMed Web of Science ®Google Scholar
• Desir B, Amre DK, Lu SE, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:139–146.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7:8–15.
   PubMed Web of Science ®Google Scholar
• Eser A, Papay P, Primas C, et al. The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's disease. Aliment Pharmacol Ther. 2012;35:292–299.
   PubMed Web of Science ®Google Scholar
• Reumaux D, Sendid B, Poulain D, et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2003;17:19–35.
   PubMed Web of Science ®Google Scholar
• Teml A, Kratzer V, Schneider B, et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol. 2003;98:2226–2231.
   PubMed Web of Science ®Google Scholar
• Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol. 2002;97:1458–1462.
   PubMed Web of Science ®Google Scholar
• Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232–1236.
   PubMed Web of Science ®Google Scholar
• van Schaik FD, Oldenburg B, Hart AR, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut. 2013;62:683–688.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Kugathasan S, Dubinsky M, et al. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology?. Inflamm Bowel Dis. 2009;15:714–719.
   PubMed Web of Science ®Google Scholar
• Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235–2241.
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996;110:1810–1819.
   PubMed Web of Science ®Google Scholar
• Hoie O, Aamodt G, Vermeire S, et al. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. J Crohns Colitis. 2008;2:114–122.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Landers CJ, Tremaine WJ, et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71:431–436.
   PubMed Web of Science ®Google Scholar
• Nakamura RM, Matsutani M, Barry M. Advances in clinical laboratory tests for inflammatory bowel disease. Clin Chim Acta. 2003;335:9–20.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Turner D. Differences in the management of pediatric and adult onset ulcerative colitis–lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. J Crohns Colitis. 2014;8:1–4.
   PubMed Web of Science ®Google Scholar
• Plevy S, Silverberg MS, Lockton S, et al. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients. Inflamm Bowel Dis. 2013;19:1139–1148.
   PubMed Web of Science ®Google Scholar
• Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788–791.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822–829.
   PubMed Web of Science ®Google Scholar
• Oudkerk Pool M, Ellerbroek PM, Ridwan BU, et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut. 1993;34:46–50.
   PubMed Web of Science ®Google Scholar
• Lindgren S, Floren CH, Lindhagen T, et al. Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission. Eur J Gastroenterol Hepatol. 1995;7:563–568.
   PubMed Web of Science ®Google Scholar
• Reumaux D, Colombel JF, Masy E, et al. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflamm Bowel Dis. 2000;6:270–274.
   PubMed Web of Science ®Google Scholar
• Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:199–205.
   PubMed Web of Science ®Google Scholar